Evidence map›Paper›PMID 24517344›Full record

ArticleRespiratory research2014

Impact of heterozygote CFTR mutations in COPD patients with chronic bronchitis.

S Vamsee Raju, Jody H Tate, Sandra K G Peacock, Ping Fang, Robert A Oster, Mark T Dransfield, Steven M Rowe

Open access · goldAbstract read
In one paragraph

Article in Respiratory research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. The European respiratory journal · 2022
    Pooled it
  2. Trial
  3. Article
  4. Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL).Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2024
    Observational
  5. Animal models and mechanisms of tobacco smoke-induced chronic obstructive pulmonary disease (COPD).Journal of toxicology and environmental health. Part B, Critical reviews · 2023
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Tobacco smoke exposure limits the therapeutic benefit of tezacaftor/ivacaftor in pediatric patients with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021
    Article
  12. Host genetic effects in pneumonia.American journal of human genetics · 2021
    Article
  13. Article
  14. CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways.European respiratory review : an official journal of the European Respiratory Society · 2020
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

S Vamsee Raju
Jody H Tate
Sandra K G Peacock
Ping Fang
Robert A Oster
Mark T Dransfield
Steven M RoweDepartment of Medicine, University of Alabama at Birmingham, MCLM 706 1918 University Blvd,, Birmingham, AL, USA. smrowe@uab.edu.
University of Alabama at Birmingham · USBaylor Genetics · US

Funding

UAB CF Research and Translation Core CenterP30DK072482 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI David M. Bedwell · 2007 to 2026
$23.0M
UAB CENTER FOR CLINICAL AND TRANSLATIONAL SCIENCE (CCTS) UL1: BPCAUL1RR025777 · NCRR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GUAY-WOODFORD, LISA MARIE · 2008 to 2011
$22.3M
COPD Clinical Research Network - Data Coordinating CenterU10HL074424 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI CONNETT, JOHN E · 2003 to 2011
$21.0M
Molecular Pathogenesis and Phenotype of Acquired CFTR Dysfunction in COPDR01HL105487 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROWE, STEVEN MARK · 2011 to 2016
$2.7M
NCRR NIH HHS 5UL 1RR025777NHLBI NIH HHS R01 HL105487NHLBI NIH HHS U10 HL074424NIDDK NIH HHS P30 DK072482
6 · The paper itself

Abstract

backgroundCigarette smoking causes Chronic Obstructive Pulmonary Disease (COPD), the 3rd leading cause of death in the U.S. CFTR ion transport dysfunction has been implicated in COPD pathogenesis, and is associated with chronic bronchitis. However, susceptibility to smoke induced lung injury is variable and the underlying genetic contributors remain unclear. We hypothesized that presence of CFTR mutation heterozygosity may alter susceptibility to cigarette smoke induced CFTR dysfunction. Consequently, COPD patients with chronic bronchitis may have a higher rate of CFTR mutations compared to the general population.

methodsPrimary human bronchial epithelial cells derived from F508del CFTR heterozygotes and mice with (CFTR+/-) and without (CFTR+/+) CFTR heterozygosity were exposed to whole cigarette smoke (WCS); CFTR-dependent ion transport was assessed by Ussing chamber electrophysiology and nasal potential difference measurements, respectively. Caucasians with COPD and chronic bronchitis, age 40 to 80 with FEV1/FVC < 0.70 and FEV1 < 60% predicted, were selected for genetic analysis from participants in the NIH COPD Clinical Research Network's Azithromycin for Prevention of Exacerbations of COPD in comparison to 32,900 Caucasian women who underwent prenatal genetic testing. Genetic analysis involved an allele-specific genotyping of 89 CFTR mutations.

resultsExposure to WCS caused a pronounced reduction in CFTR activity in both CFTR (+/+) cells and F508del CFTR (+/-) cells; however, neither the degree of decrement (44.7% wild-type vs. 53.5% F508del heterozygous, P = NS) nor the residual CFTR activity were altered by CFTR heterozygosity. Similarly, WCS caused a marked reduction in CFTR activity measured by NPD in both wild type and CFTR heterozygous mice, but the severity of decrement (91.1% wild type vs. 47.7% CF heterozygous, P = NS) and the residual activity were not significantly affected by CFTR genetic status. Five of 127 (3.9%) COPD patients with chronic bronchitis were heterozygous for CFTR mutations which was not significantly different from controls (4.5%) (P = NS).

conclusionsThe magnitude of WCS induced reductions in CFTR activity was not affected by the presence of CFTR mutation heterozygosity. CFTR mutations do not increase the risk of COPD with chronic bronchitis. CFTR dysfunction due to smoking is primarily an acquired phenomenon and is not affected by the presence of congenital CFTR mutations.

Indexed as

Genetic Carrier ScreeningAdultAgedAged, 80 and overAnimalsBronchitis, ChronicCase-Control StudiesCystic Fibrosis Transmembrane Conductance RegulatorFemaleHumansInhalation ExposureMaleMiceMice, Inbred CFTRMice, KnockoutMiddle AgedCFTR protein, humanCystic Fibrosis Transmembrane Conductance Regulator

Identifiers

PMID24517344
PMCPMC3925354
OpenAlexW2167175322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.